1. 1 *Report IIB(R) 27/2006 - The CoStar Stent (Conor) was also tested but is not shown in this report as it only presents the commercially available stents Independent laboratory Report IIB(R) 27/2006 - Institut für ImplantatTechnologie und Biomaterialien e.V Rostock – Germany, 2006 Comparative Investigation of Coronary Stent Systems (DES)

2. 2 *Report IIB(R) 27/2006 - The CoStar Stent (Conor) was also tested but is not shown in this report as it only presents the commercially available stents Test Samples* All stents were DES systems The study included the balloon-expandable coronary stent systems according to the table below. All stent systems were provided as complete systems with the stents pre-mounted on balloon catheters. #ManufacturerTypeDimensions (mm) 3BiosensorsBioMatrix3.0 x 14 3MedtronicEndeavor3.0 x 18 3B.BraunCoroflex Please3.0 x 15 3AbbottXience V3.0 x 15 3Boston ScientificTaxus Liberté3.0 x 16 3CordisCypher Select+3.0 x 18

3. 3 *Report IIB(R) 27/2006 - The CoStar Stent (Conor) was also tested but is not shown in this report as it only presents the commercially available stents Key Highlights

4. 4 *Report IIB(R) 27/2006 - The CoStar Stent (Conor) was also tested but is not shown in this report as it only presents the commercially available stents Side branch access Explanation: Measurement of the largest possible opening in the stent structure which could be used for side branch access –Diameter measured in mm –Large diameter  good side branch access

5. 5 *Report IIB(R) 27/2006 - The CoStar Stent (Conor) was also tested but is not shown in this report as it only presents the commercially available stents BioMatrix ® 3.0 x 14 mm Taxus Liberté 3.0 x 16 mm BioMatrix demonstrated the best side branch access Diameter of the largest possible opening in the stents as a measure of side branch accessibility

6. 6 *Report IIB(R) 27/2006 - The CoStar Stent (Conor) was also tested but is not shown in this report as it only presents the commercially available stents Radial strength Explanation: Scaffolding provided by the stent to support the narrowed artery –Measured as the pressure at which the stent will collapse –High collapse pressure  high radial strength

7. 7 *Report IIB(R) 27/2006 - The CoStar Stent (Conor) was also tested but is not shown in this report as it only presents the commercially available stents BioMatrix demonstrated excellent radial strength Collapse pressure of the expanded stent as the measure of radial strength

8. 8 *Report IIB(R) 27/2006 - The CoStar Stent (Conor) was also tested but is not shown in this report as it only presents the commercially available stents Stent profile Explanation: Mean diameter of the stent mounted on the delivery system –A mean value calculated from stent diameter measurements taken over the entire stent length –Low stent profile  considered good crossability

9. 9 *Report IIB(R) 27/2006 - The CoStar Stent (Conor) was also tested but is not shown in this report as it only presents the commercially available stents BioMatrix is competitive in terms of stent profile Stent profile of crimped stents as mean values over the entire stent length

10. 10 *Report IIB(R) 27/2006 - The CoStar Stent (Conor) was also tested but is not shown in this report as it only presents the commercially available stents Crossability Explanation: Ability of the stent to cross a stenotic lesion using an artery model –Measured by the mean distal force required to cross the stenotic lesion –The less force needed, the better the performance in terms of crossability

11. 11 *Report IIB(R) 27/2006 - The CoStar Stent (Conor) was also tested but is not shown in this report as it only presents the commercially available stents BioMatrix demonstrated excellent crossability Mean distal Force F dist of crossability test, stenosis model type 2,d=1.4mm, as a measure of crossability

12. 12 *Report IIB(R) 27/2006 - The CoStar Stent (Conor) was also tested but is not shown in this report as it only presents the commercially available stents Trackability Explanation: Ability of the catheter to track along the guide wire (Total distance of advancement in testing for all stents = 220mm) –Measured by the force needed to track along the guide wire –The less force needed, the better the performance in terms of trackability

13. 13 *Report IIB(R) 27/2006 - The CoStar Stent (Conor) was also tested but is not shown in this report as it only presents the commercially available stents Mean track force F prox as a measure of trackability (coronary vessel model, path5) BioMatrix performed best in Trackability – Allowing navigation through tortuous anatomy

14. 14 *Report IIB(R) 27/2006 - The CoStar Stent (Conor) was also tested but is not shown in this report as it only presents the commercially available stents Foreshortening Explanation: Change in stent length after expansion –Measured in % of length change Positive % means the stent length increases Negative % means the stent length decreases –low % of change  small change in stent length

15. 15 *Report IIB(R) 27/2006 - The CoStar Stent (Conor) was also tested but is not shown in this report as it only presents the commercially available stents BioMatrix demonstrated the smallest length change – to allow for more accurate stent placement Test results for the stent length before and after expansion Length change of stents due to expansion (a negative sign means a stent shortening)

16. 16 *Report IIB(R) 27/2006 - The CoStar Stent (Conor) was also tested but is not shown in this report as it only presents the commercially available stents Elastic recoil Explanation: Elastic relaxation of stent after expansion e.g. ability of the stent to spring back after expansion –Measured as the difference between the stent diameter at deployment and after deflation of the balloon. –The smaller the % change in diameter, the lower % of stent recoil

17. 17 *Report IIB(R) 27/2006 - The CoStar Stent (Conor) was also tested but is not shown in this report as it only presents the commercially available stents BioMatrix demonstrated a low elastic recoil – to ensure complete stent apposition

18. 18 *Report IIB(R) 27/2006 - The CoStar Stent (Conor) was also tested but is not shown in this report as it only presents the commercially available stents Radiopacity Explanation: Ability to see the stent on an angiogram (X-ray) –X-ray (angiogram) imaging of both the crimped stent and the stent deployed, assessed by a measure of visibility

19. 19 *Report IIB(R) 27/2006 - The CoStar Stent (Conor) was also tested but is not shown in this report as it only presents the commercially available stents BioMatrix demonstrated good visibility – to ensure precise stent placement

20. 20 *Report IIB(R) 27/2006 - The CoStar Stent (Conor) was also tested but is not shown in this report as it only presents the commercially available stents The BioMatrix ® stent platform demonstrates superior performance over market leading products in several performance characteristics

21. 21 *Report IIB(R) 27/2006 - The CoStar Stent (Conor) was also tested but is not shown in this report as it only presents the commercially available stents Rue de Lausanne 29 – 1110 MORGES – Switzerland Tel. (41) 0 21 804 80 00 – Fax (41) 0 21 804 80 01 customer@biosensors.com